Zegalogue

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Type 1 DiabetesType 1 Diabetes MellitusHypoglycemiaHyperinsulinism

384 competitors in Type 1 Diabetes

#DrugCompanyPhaseTrials

1

Zegalogue

Zealand Pharma

Phase 3

42

Symlin

AstraZeneca

Preclinical

43

Symlin

AstraZeneca

Preclinical

34

Aldomet

Neurocrine Biosciences

Preclinical

25

Pitocin

RRetrophin

Preclinical

16

Glargine

Eli Lilly

Preclinical

47

Feraheme

AAzurity Pharmaceuticals

Preclinical

18

Foradil

Viatris

Preclinical

19

Cytoxan

BBaxter Healthcare Corporation

Preclinical

110

SGLT2 Inhibitor

Eli Lilly

Preclinical

1Show 11 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Type 1 Diabetes4 trials

Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents

Completed·Novo Nordisk·Phase 1·NCT06588504·38 enrolled

A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects

Completed·Zealand Pharma·Phase 3·NCT03378635·170 enrolled

Low-dose Dasiglucagon for Prevention of Insulin-Induced Hypoglycemia in People With Type 1 Diabetes

Completed·SSteno Diabetes Center Copenhagen·Phase 2·NCT04449692·20 enrolled

Show 1 more trial

Pen-Administered Low-Dose Dasiglucagon for Prevention and Treatment of Hypoglycemia in People With Type 1 Diabetes

Completed·SSteno Diabetes Center Copenhagen·Phase 2·NCT04764968·24 enrolled

Hypoglycemia4 trials

Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children

Completed·Zealand Pharma·Phase 3·NCT03667053·42 enrolled

Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM

Completed·Zealand Pharma·Phase 3·NCT03688711·45 enrolled

Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated Adults

Withdrawn·Zealand Pharma·Phase 2·NCT04824872

Show 1 more trial

A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D

Completed·Zealand Pharma·Phase 3·NCT05378672·8 enrolled

Hyperinsulinism2 trials

A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

Completed·Zealand Pharma·Phase 3·NCT03777176·32 enrolled

Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

Completed·Zealand Pharma·Phase 2/3·NCT04172441·12 enrolled

Efficacy and Safety1 trial

A Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With T1DM

Completed·Zealand Pharma·Phase 3·NCT03895697·92 enrolled

Type 1 Diabetes Mellitus1 trial

A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus

Completed·Zealand Pharma·Phase 3·NCT03216226·112 enrolled

4 more indications

Treatment1 trial

Treatment of Post-bariatric Hypoglycaemia

Completed·FFilip Krag Knop·Phase 2·NCT04836273·24 enrolled

MPA1 trial

Evaluation of the Safety, Tolerability and Bioavailability of Dasiglucagon Following Subcutaneous (SC) Compared to IV Administration

Completed·Zealand Pharma·Phase 1·NCT03735225·60 enrolled

Congenital Hyperinsulinism1 trial

An Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon for the Treatment of Children With Congenital Hyperinsulinism

Active, not recruiting·Zealand Pharma·Phase 3·NCT03941236·42 enrolled

Unspecified2 trials

The Bihormonal iLet Bionic Pancreas Feasibility Study

Completed·MMassachusetts General Hospital·Phase 2/3·NCT03840278·12 enrolled

A Stable Glucagon Analog Administered by a Bihormonal Closed Loop System

Withdrawn·IInreda Diabetic B.V.·Phase 2·NCT05454709

Regulatory

FDA Approval Timeline[4]

Details

Drug Info

Patent Landscape[5]

Related News